Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RYTM
RYTM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RYTM News
Rhythm Pharmaceuticals Stock Soars with Significant Growth Potential
Feb 02 2026
NASDAQ.COM
Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
Feb 02 2026
Fool
Rhythm Pharmaceuticals Reports $194M in 2025 IMCIVREE Sales
Jan 09 2026
Newsfilter
Rhythm Pharma Hits the Right Note with Promising Early Results from PWS Trial
Dec 11 2025
Benzinga
Rhythm Pharma to Share Initial Phase 2 Results of Setmelanotide for Prader-Willi Syndrome Today
Dec 11 2025
NASDAQ.COM
Rhythm Pharmaceuticals to Disclose Preliminary Data from PWS Trial on December 11
Dec 10 2025
Globenewswire
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
Dec 04 2025
Barron's
S&P 500 Futures Rise in Pre-Market Session; Centene and Millicom International Cellular Take the Lead
Nov 24 2025
Barron's
Canaccord Genuity Reaffirms Buy Rating on Rhythm Pharmaceuticals and Increases Price Target to $114
Nov 10 2025
Benzinga
Rythm Pharmaceuticals' CTO Offloads 9,748 Shares for $1.1 Million
Nov 08 2025
NASDAQ.COM
Needham Keeps Buy Rating on Rhythm Pharmaceuticals, Reduces Price Target to $120
Nov 07 2025
Benzinga
US FDA Prolongs Evaluation of Rhythm's Treatment for Obesity Linked to Brain Damage
Nov 07 2025
Reuters
Rhythm Pharmaceuticals Reveals FDA Extension for IMCIVREE® (setmelanotide) Review for Acquired Hypothalamic Obesity Patients
Nov 07 2025
Newsfilter
Rhythm Pharmaceuticals, Inc. Reports Larger Q3 Loss, Falls Short of Expectations
Nov 04 2025
NASDAQ.COM
Obesity Therapeutics Market Experiences Rapid Growth Driven by GLP-1 Advancements and Increasing Oral Treatment Options | DataM Intelligence
Oct 30 2025
Yahoo Finance
Explore the Details: TMSL Projected to Rise by 16%
Oct 10 2025
NASDAQ.COM
Show More News
